Petronilla Staubach1, Anton Scharl2, Atanas Ignatov3, Olaf Ortmann3, Elisabeth C Inwald3, Thomas Hildebrandt4, Michael Gerken5, Monika Klinkhammer-Schalke5, Sophia Scharl6, Thomas Papathemelis2. 1. Department of Obstetrics and Gynecology, St. Marien Hospital, Amberg, Germany. petronillastaubach@gmx.de. 2. Department of Obstetrics and Gynecology, St. Marien Hospital, Amberg, Germany. 3. Department of Obstetrics and Gynecology, University Hospital Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. 4. Department of Obstetrics and Gynecology, University Hospital Erlangen-Nuremberg, Maximilianspl. 2, 91054, Erlangen, Germany. 5. Tumor Center of the University of Regensburg, Institute for Quality Assurance and Health Services Research, Regensburg, Germany. 6. Department of Radiooncology and Radiotherapy, Technical University Hospital Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Abstract
PURPOSE: The usage of radioactive Technetium99m (Tc99m) colloid for the purpose of sentinel lymph node biopsy (SLNB) in early breast cancer is considered the gold standard in Germany. However, new tracers, such as near-infrared (NIR) imaging agents like indocyanine green (ICG) could offer an alternative in future, as they overcome drawbacks associated with radioactive Technetium99m (Tc99m) like limited availability, high costs and radioactivity exposure for both patients and surgeons. METHODS: In this double-arm retrospective study, we sought to establish the usefulness of indocyanine green as an alternative or an addition to the conventional Technetium99m (Tc99m) in the identification of the SLN in early breast cancer. RESULTS: Among the 161 patients who underwent primary SLNB, 34 patients had at least 1 SLN with metastasis. Among these patients with SLN metastasis, 33 had the SLN detected by ICG; while 31 had the SLN detected by Tc99m. The conventional Technetium99m radiotracer failed to detect 2 patients with metastasis in this Arm of the study. Among the 87 patients who underwent SLNB after NACT, 13 patients had at least 1 SLN with metastasis. Among these 13 patients with SLN metastasis, ICG and Tc99m had detected the SLN among 12 patients, while 1 patient had been detected by ICG alone. CONCLUSIONS: Our results show that ICG is as effective as the radioisotope for SLNB even among patients who have undergone NACT. This trial is registered with the German Clinical Trial Register, ID: DRKS00013606.
PURPOSE: The usage of radioactive Technetium99m (Tc99m) colloid for the purpose of sentinel lymph node biopsy (SLNB) in early breast cancer is considered the gold standard in Germany. However, new tracers, such as near-infrared (NIR) imaging agents like indocyanine green (ICG) could offer an alternative in future, as they overcome drawbacks associated with radioactive Technetium99m (Tc99m) like limited availability, high costs and radioactivity exposure for both patients and surgeons. METHODS: In this double-arm retrospective study, we sought to establish the usefulness of indocyanine green as an alternative or an addition to the conventional Technetium99m (Tc99m) in the identification of the SLN in early breast cancer. RESULTS: Among the 161 patients who underwent primary SLNB, 34 patients had at least 1 SLN with metastasis. Among these patients with SLN metastasis, 33 had the SLN detected by ICG; while 31 had the SLN detected by Tc99m. The conventional Technetium99m radiotracer failed to detect 2 patients with metastasis in this Arm of the study. Among the 87 patients who underwent SLNB after NACT, 13 patients had at least 1 SLN with metastasis. Among these 13 patients with SLN metastasis, ICG and Tc99m had detected the SLN among 12 patients, while 1 patient had been detected by ICG alone. CONCLUSIONS: Our results show that ICG is as effective as the radioisotope for SLNB even among patients who have undergone NACT. This trial is registered with the German Clinical Trial Register, ID: DRKS00013606.
Entities:
Keywords:
Breast cancer; Indocyanine green; Neoadjuvant therapy; Sentinel biopsy
Authors: Armando Sardi; Ethan Spiegler; Jean Colandrea; David Frishberg; Hardeep Sing; Patricia Regan; Adil Totoonchie; Deepak Merchant; Stephen Hochuli; Viney Setya; John A Singer Journal: Am Surg Date: 2002-01 Impact factor: 0.688
Authors: Karina Cox; Jennifer Weeks; Pippa Mills; Ritchie Chalmers; Haresh Devalia; David Fish; Ali Sever Journal: Ann Surg Oncol Date: 2015-05-20 Impact factor: 5.344
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark Journal: Lancet Oncol Date: 2007-10 Impact factor: 41.316
Authors: Thomas Papathemelis; Evi Jablonski; Anton Scharl; Tanja Hauzenberger; Michael Gerken; Monika Klinkhammer-Schalke; Matthias Hipp; Sophia Scharl Journal: Biomed Res Int Date: 2018-03-26 Impact factor: 3.411